Loading
INCA33890 is an experimental investigational agent whose form is not stated in the registry from Incyte in phase 3 trials for colorectal cancer, with its target not yet stated publicly.
INCA33890 is an investigational agent whose form is not stated in the registry developed by Incyte. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: INCA33890 will be administered at protocol defined dose. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07284849 (A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer), in colorectal cancer. The largest, NCT07284849, plans to enrol 700 participants with primary completion expected 2028-12-29. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.One arm of INCA33890 binds its target on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"INCA33890" OR ABSTRACT:"INCA33890") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about INCA33890, not a curated reading list.
Shares Incyte and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.